Intuitive Surgical, Inc. $ISRG Stock Purchased by Trillium Asset Management LLC

Trillium Asset Management LLC boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 78.4% in the 3rd quarter, Holdings Channel reports. The firm owned 50,395 shares of the medical equipment provider’s stock after buying an additional 22,145 shares during the quarter. Trillium Asset Management LLC’s holdings in Intuitive Surgical were worth $20,493,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in shares of Intuitive Surgical by 3.3% during the first quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after purchasing an additional 116,292 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Intuitive Surgical in the second quarter valued at about $1,335,753,000. Amundi grew its stake in shares of Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after buying an additional 193,096 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Intuitive Surgical by 95.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after buying an additional 1,027,475 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Intuitive Surgical by 10.8% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,893,485 shares of the medical equipment provider’s stock valued at $769,948,000 after buying an additional 184,044 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ISRG shares. Sanford C. Bernstein reissued an “outperform” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $450.00 to $475.00 and gave the company an “overweight” rating in a research report on Wednesday, October 21st. HSBC lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 price objective on the stock. in a research note on Thursday, July 30th. Piper Sandler reiterated an “overweight” rating on shares of Intuitive Surgical in a research note on Friday, August 21st. Finally, Oppenheimer reissued an “outperform” rating and set a $500.00 target price on shares of Intuitive Surgical in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $493.54.

Intuitive Surgical Trading Up 0.8%

ISRG stock traded up $3.70 during midday trading on Friday, hitting $443.59. 1,604,248 shares of the company’s stock were exchanged, compared to its average volume of 2,787,457. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88. The firm has a 50 day moving average price of $417.59 and a 200-day moving average price of $429.98. The stock has a market capitalization of $153.77 billion, a price-to-earnings ratio of 53.64, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. Intuitive Surgical’s quarterly revenue was up 21.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.40 EPS. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $458.15, for a total value of $183,260.00. Following the completion of the sale, the executive vice president owned 6,236 shares in the company, valued at approximately $2,857,023.40. The trade was a 6.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig Barratt sold 1,150 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $460.00, for a total transaction of $529,000.00. Following the completion of the sale, the director directly owned 1,150 shares in the company, valued at $529,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 39,456 shares of company stock valued at $17,769,124. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.